# Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Study · id `cardio:ct-nct07037433` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07037433](<https://clinicaltrials.gov/study/NCT07037433>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07037433

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 12800 participants.

## Technical summary

Registry record NCT07037433. Randomized; double masking; primary purpose treatment. Start 2025-07-25 (actual); primary completion 2028-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 12800 participants (planned count; ClinicalTrials.gov record NCT07037433, source copy `cardio:ctgov-nct07037433-2026-10-29`, retrieved 2026-10-31)
- Started: 2025-07-25 (actual) (ClinicalTrials.gov record NCT07037433, source copy `cardio:ctgov-nct07037433-2026-10-29`, retrieved 2026-10-31)
- Primary completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT07037433, source copy `cardio:ctgov-nct07037433-2026-10-29`, retrieved 2026-10-31)
- Completion: 2030-09-29 (anticipated) (ClinicalTrials.gov record NCT07037433, source copy `cardio:ctgov-nct07037433-2026-10-29`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; Finland; France; Germany; Greece; Hong Kong SAR China; Hungary; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Puerto Rico; Romania; Singapore; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT07037433, source copy `cardio:ctgov-nct07037433-2026-10-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07037433-2026-10-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Acronym: MARITIME-CV
- Condition: Atherosclerotic Cardiovascular Disease
- Condition: Overweight
- Condition: Obesity
- Intervention (Drug): Maridebart Cafraglutide
- Intervention (Drug): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: a65f1a5813e7720138a824274533bcaacd635ca192eec1a3bcc624a71c74fc01
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
